LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
19 hedge funds and large institutions have $10.6M invested in LAVA Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
4% more capital invested
Capital invested by funds: $10.2M → $10.6M (+$411K)
0.01% more ownership
Funds ownership: 30.6% → 30.61% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5% less funds holding
Funds holding: 20 → 19 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$59.6K |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$34.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$18.1K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$12.7K |
| 5 |
LDNAM
Lepercq De Neuflize Asset Management
New York
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$61.5K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$30.9K |
| 3 |
Two Sigma Investments
New York
|
-$29.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.54K |
| 5 |
JP Morgan Chase
New York
|
-$1.65K |
LVTX Hedge Fund Activity: Q2 2025 in Review
19 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q2 2025, worth a combined $10.6M — up 4% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LVTX and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $59.6K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $61.5K sold.
- 19 institutional investors held LAVA Therapeutics (LVTX) as of Q2 2025, down from 20 in Q1 2025.
- Funds reported $10.6M of LAVA Therapeutics stock for Q2 2025, up 4% quarter-over-quarter.
- 3 funds opened new LAVA Therapeutics positions in Q2 2025 and 4 closed out, a net change of -1 holder.
- The largest LAVA Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $59.6K added.
- The largest LAVA Therapeutics seller in Q2 2025 was Sphera Funds Management, an estimated $61.5K sold.
Based on aggregated 13F filings for Q2 2025.